Double-Blind, Randomized Phase III Trial of Low-Dose 13-Cisretinoic Acid in Prevention of Second Primaries in Head and Neck Cancer: Long-Term Follow-up of a Trial of the ECOG-ACRIN Cancer Research Group (C0590)

BACKGROUND: 13-Cisretinoic acid (13-CRA) is a synthetic Vitamin A derivative. High-dose 13-CRA in patients with squamous cell cancers of the head and neck (SCCHN) reduces the incidence of second primary tumors (SPT). We report long-term results of a Phase III randomized trial that compared low-dose...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Bhatia, Aarti K., Lee, Ju-Whei, Pinto, Harlan A., Jacobs, Charlotte D., Limburg, Paul J., Rubin, Philip, Arusell, Robert M., Dunphy, Eamonn P., Khandekar, Janardan D., Reiner, Seth A., Baez-Diaz, Luis, Celano, Paul, Li, Shuli, Li, Yi, Burtness, Barbara A., Adams, George L., Pandya, Kishan J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5693641/
https://ncbi.nlm.nih.gov/pubmed/28786105
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30920
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
A carregar...

Registos relacionados